Patent SG-11201810189S-A (SG)
Title: Combination formulation of three antiviral compounds
Inventor: CHAL BEN
IPC: A61K9/20
Filed: 2017-06-01
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 111111411 0 11101 HOE 010 1111 1 0 013 01011101111111111 HMI IIE O EN Organization - - - ' International Bureau (10) International Publication Number (43) International Publication Date ......0\" WO 2017/210483 Al 07 December 2017 (07.12.2017) WIP0 I PCT — (51) (21) (22) (25) Filing Language: (26) (30) (71) (72) International Patent Classification: Dimitrios; c/o Gilead Pharmasset LLC, 333 Lakeside Dri- A61K 31/4188 (2006.01) A61K 9/14 (2006.01) ye, Foster City, California 94404 (US). A61K 31/7072 (2006.01) A61K 9/20 (2006.01) A61K 31/4985 (2006.01) A61P 31/14 (2006.01) (74) Agent: TANNER, Lorna L. et al.; SHEPPARD MULLIN RICHTER & HAMPTON, 379 Lytton Avenue, Palo Alto, International Application Number: California 94301-1479 (US). PCT/US2017/035539 (81) Designated States (unless otherwise indicated, for every International Filing Date: kind of national protection available): AE, AG, AL, AM, 01 June 2017 (01.06.2017) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, English DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, Publication Language: English HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, Priority Data: KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, 62/344,904 02 June 2016 (02.06.2016) US MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, Applicant: GILEAD PHARMASSET LLC [US/US]; 333 SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, Lakeside Drive, Foster City, California 94404 (US). TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. Inventors: CHAL, Ben; c/o Gilead Pharmasset LLC, 333 (84) Designated States (unless otherwise indicated, for every Lakeside Drive, Foster City, California 94404 (US). NE- kind of regional protection available): ARIPO (BW, GH, JATI, Elham; c/o Gilead Pharmasset LLC, 333 Lakeside GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, Drive, Foster City, California 94404 (US). PAKDAMAN, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, Rowchanak; c/o Gilead Pharmasset LLC, 333 Lakeside TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, Drive, Foster City, California 94404 (US). STEFANIDIS, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, = Title: COMBINATION FORMULATION 100 if < 80 r- o at 60 x o. 40 X > 20 e 0• : Disclosed are pharmaceutical comprise an effective amount disclosed are methods of use for the pharmaceutical composition. 0 compositions / I i OF THREE ANTIVIRAL COMPOUNDS Control: VOX SDD tablet (100 mg) + SOFNEL tablet (400/100 mg) . — (54) = = = = = = = = = — = = = = — = —0— VOX SDD Tablet (100 mg) + SOFNEL SDD Tablet (400/100 mg) —v.-- 1200 mg; lactose:MCC 1:1; crascamellose sodium (Formulation A) —0-- 1200 mg; lactose:MCC 1:0; crascamellose sodium (Formulation B) —0— 1200 mg; lactose:MCC 0:1; crascamellose sodium (Formulation C) — Il en GC 1 1' 0 1-1 ei IN ,-1 (57) N Also 10 20 30 40 50 60 Time (min) FIG. 1 compositions comprising three antiviral compounds. In particular, the pharmaceutical of velpatasvir, an effective amount of sofosbuvir, and an effective amount of voxilaprevir. [Continued on next page] WO 2017/210483 Al MIDEDIMOMOIDEIRMEM0011010111111MOMEMON MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: — as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Published: — with international search report (Art. 21(3))